2727 related articles for article (PubMed ID: 20175033)
1. Modified RECIST (mRECIST) assessment for hepatocellular carcinoma.
Lencioni R; Llovet JM
Semin Liver Dis; 2010 Feb; 30(1):52-60. PubMed ID: 20175033
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
Kawaoka T; Aikata H; Murakami E; Nakahara T; Naeshiro N; Tanaka M; Honda Y; Miyaki D; Nagaoki Y; Takaki S; Hiramatsu A; Waki K; Takahashi S; Chayama K
Oncology; 2012; 83(4):192-200. PubMed ID: 22890083
[TBL] [Abstract][Full Text] [Related]
3. Design and endpoints of clinical trials in hepatocellular carcinoma.
Llovet JM; Di Bisceglie AM; Bruix J; Kramer BS; Lencioni R; Zhu AX; Sherman M; Schwartz M; Lotze M; Talwalkar J; Gores GJ;
J Natl Cancer Inst; 2008 May; 100(10):698-711. PubMed ID: 18477802
[TBL] [Abstract][Full Text] [Related]
4. The true role of mRECIST guideline: does it really estimate viable tumor or merely improve accuracy in hepatocellular carcinoma response evaluation?
Liu Q; Li A; Sun S; Luo R; Chen F
J BUON; 2014; 19(2):398-405. PubMed ID: 24965398
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of tumor response after locoregional therapies in hepatocellular carcinoma: are response evaluation criteria in solid tumors reliable?
Forner A; Ayuso C; Varela M; Rimola J; Hessheimer AJ; de Lope CR; Reig M; Bianchi L; Llovet JM; Bruix J
Cancer; 2009 Feb; 115(3):616-23. PubMed ID: 19117042
[TBL] [Abstract][Full Text] [Related]
6. Selection of response criteria for clinical trials of sarcoma treatment.
Schuetze SM; Baker LH; Benjamin RS; Canetta R
Oncologist; 2008; 13 Suppl 2():32-40. PubMed ID: 18434637
[TBL] [Abstract][Full Text] [Related]
7. A statistical simulation study finds discordance between WHO criteria and RECIST guideline.
Mazumdar M; Smith A; Schwartz LH
J Clin Epidemiol; 2004 Apr; 57(4):358-65. PubMed ID: 15135836
[TBL] [Abstract][Full Text] [Related]
8. Locoregional radiological treatment for hepatocellular carcinoma; Which, when and how?
Meza-Junco J; Montano-Loza AJ; Liu DM; Sawyer MB; Bain VG; Ma M; Owen R
Cancer Treat Rev; 2012 Feb; 38(1):54-62. PubMed ID: 21726960
[TBL] [Abstract][Full Text] [Related]
9. Tumor response evaluation in oncology: current update.
Shanbhogue AK; Karnad AB; Prasad SR
J Comput Assist Tomogr; 2010 Jul; 34(4):479-84. PubMed ID: 20657213
[TBL] [Abstract][Full Text] [Related]
10. A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead.
Poon RT; Tso WK; Pang RW; Ng KK; Woo R; Tai KS; Fan ST
Clin Gastroenterol Hepatol; 2007 Sep; 5(9):1100-8. PubMed ID: 17627902
[TBL] [Abstract][Full Text] [Related]
11. Comparison of tumor response by Response Evaluation Criteria in Solid Tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma.
Edeline J; Boucher E; Rolland Y; Vauléon E; Pracht M; Perrin C; Le Roux C; Raoul JL
Cancer; 2012 Jan; 118(1):147-56. PubMed ID: 21713764
[TBL] [Abstract][Full Text] [Related]
12. Comparison of different tumor response criteria in patients with hepatocellular carcinoma after systemic therapy with the multikinase inhibitor sorafenib.
Spira D; Fenchel M; Lauer UM; Claussen CD; Gregor M; Bitzer M; Horger M
Acad Radiol; 2011 Jan; 18(1):89-96. PubMed ID: 20926315
[TBL] [Abstract][Full Text] [Related]
13. Beyond RECIST: molecular and functional imaging techniques for evaluation of response to targeted therapy.
Desar IM; van Herpen CM; van Laarhoven HW; Barentsz JO; Oyen WJ; van der Graaf WT
Cancer Treat Rev; 2009 Jun; 35(4):309-21. PubMed ID: 19136215
[TBL] [Abstract][Full Text] [Related]
14. [Hepatocellular carcinoma].
Kondo S; Ueno H; Morizane C; Okusaka T
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1219-23. PubMed ID: 20647702
[TBL] [Abstract][Full Text] [Related]
15. Evolution from WHO to EASL and mRECIST for hepatocellular carcinoma: considerations for tumor response assessment.
Kim MN; Kim BK; Han KH; Kim SU
Expert Rev Gastroenterol Hepatol; 2015 Mar; 9(3):335-48. PubMed ID: 25370168
[TBL] [Abstract][Full Text] [Related]
16. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology.
Kudo M; Okanoue T;
Oncology; 2007; 72 Suppl 1():2-15. PubMed ID: 18087177
[TBL] [Abstract][Full Text] [Related]
17. Assessing Imaging Response to Therapy.
Minocha J; Lewandowski RJ
Radiol Clin North Am; 2015 Sep; 53(5):1077-88. PubMed ID: 26321455
[TBL] [Abstract][Full Text] [Related]
18. Response assessment in clinical trials: implications for sarcoma clinical trial design.
Jaffe CC
Oncologist; 2008; 13 Suppl 2():14-8. PubMed ID: 18434633
[TBL] [Abstract][Full Text] [Related]
19. Imaging response in the primary index lesion and clinical outcomes following transarterial locoregional therapy for hepatocellular carcinoma.
Riaz A; Miller FH; Kulik LM; Nikolaidis P; Yaghmai V; Lewandowski RJ; Mulcahy MF; Ryu RK; Sato KT; Gupta R; Wang E; Baker T; Abecassis M; Benson AB; Nemcek AA; Omary R; Salem R
JAMA; 2010 Mar; 303(11):1062-9. PubMed ID: 20233824
[TBL] [Abstract][Full Text] [Related]
20. State of the art: radiolabeled microspheres treatment for liver malignancies.
Deleporte A; Flamen P; Hendlisz A
Expert Opin Pharmacother; 2010 Mar; 11(4):579-86. PubMed ID: 20163269
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
